Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H18N2O |
Molecular Weight | 242.3162 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C\C=C1/[C@@H]2CC3=C(C=CC(=O)N3)[C@@]1(N)CC(C)=C2
InChI
InChIKey=ZRJBHWIHUMBLCN-YQEJDHNASA-N
InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1
DescriptionSources: https://doi.org/10.1016/j.jalz.2009.05.218 | https://adisinsight.springer.com/drugs/800016260http://www.webmd.com/vitamins-supplements/ingredientmono-764-huperzine%20a.aspxCurator's Comment: description was created based on several sources, including:
https://www.braintropic.com/nootropics/huperzine-a/ | https://www.drugs.com/npc/huperzine-a.html | http://medind.nic.in/daa/t11/i1/daat11i1p177.pdf
Sources: https://doi.org/10.1016/j.jalz.2009.05.218 | https://adisinsight.springer.com/drugs/800016260http://www.webmd.com/vitamins-supplements/ingredientmono-764-huperzine%20a.aspx
Curator's Comment: description was created based on several sources, including:
https://www.braintropic.com/nootropics/huperzine-a/ | https://www.drugs.com/npc/huperzine-a.html | http://medind.nic.in/daa/t11/i1/daat11i1p177.pdf
Huperzine A is a plant alkaloid derived from Club moss plant, Huperzine serrata, which is a member or the Lycopodium species. Huperzine-A is in phase III clinical trial in the USA (Alzheimer disease) and is available as a dietary supplement. It selectively and reversibly inhibits acetylcholinesterase. Huperzine A is also a NMDA receptor antagonist, which protects the brain against glutamate induced damage, and it increases nerve growth factor levels. Huperzine A is used for Alzheimer's disease, memory and learning enhancement, and age-related memory impairment. It is also used for treating a muscle disease called myasthenia gravis, for increasing alertness and energy, and for protecting against agents that damage the nerves such as nerve gases. It can cause some side effects including nausea, diarrhea, vomiting, sweating, blurred vision, slurred speech, restlessness, loss of appetite, contraction and twitching of muscle fibers, cramping, increased saliva and urine, inability to control urination, high blood pressure, and slowed heart rate. Various medications used for glaucoma, Alzheimer's disease, and other conditions (Cholinergic drugs) interacts with Huperzine A.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10375798 |
64.7 nM [IC50] | ||
Target ID: CHEMBL1907608 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10437121 |
0.5 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Huperzine A Approved UseHuperzine A can be used as a memory enhancer. It can also be taken regularly to help protect against age-related declines in memory. |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. | 1995 Jun-Jul |
|
Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. | 1998 May 22 |
|
Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. | 2002 Oct |
|
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. | 2004 May 6 |
|
The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice. | 2008 Sep 16 |
|
BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. | 2009 Jun 24 |
|
Coadministration of huperzine A and ligustrazine phosphate effectively reverses scopolamine-induced amnesia in rats. | 2010 Oct |
|
The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat. | 2013 Sep 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://doi.org/10.1016/j.jalz.2009.05.218
Patients in the mimopezil arm received 1 mg mimopezil daily orally during the 1-month titration period, 9 mg mimopezil as s.c. implants in the 1-month maintenance I period, and 12 mg mimopezil as s.c. implants in the 4-month maintenance II period.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7898122
The synthetic racemic mixture (+/-)-huperzine-A was 3 times less potent than (-)-huperzine-A in vitro (IC50s of 3 x 10(-7) M and 10(-7) M, respectively) because the former consisted of a racemic mixture of the compound in which the (+)-huperzine component was considerably less potent (IC50 = 7 x 10(-6) M).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
744420
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
||
|
DSLD |
708 (Number of products:164)
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
||
|
NCI_THESAURUS |
C66880
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
||
|
DSLD |
3336 (Number of products:266)
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
559916
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
885322
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
178022
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
HUPERZINE A
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
DB04864
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
SUB127430
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
102518-79-6
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
100000153436
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
m6064
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
854026
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
DTXSID8046038
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
2267703
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
0111871I23
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
0111871I23
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
SUB33678
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
ALTERNATIVE | |||
|
C97271
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
C050426
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY | |||
|
78330
Created by
admin on Fri Dec 15 16:28:04 GMT 2023 , Edited by admin on Fri Dec 15 16:28:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)